Humacyte, Inc. (HUMA) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 138 institutional investors hold a position in Humacyte, Inc. (NASDAQ:HUMA).

• Institutional ownership in Humacyte edged up to 34.1% in December 2025, compared to 28.5% in September 2025.
• Institutional share ownership changed by 22.40% QoQ, while the number of institutional owners saw a decrease of 13.21% YoY.
• A review of institutional activity for Humacyte shows 73 of 138 filers increasing their positions, while 33 reduced their stake, and 32 remained unchanged.
• The total number of shares held by institutions in Humacyte increased to 54.83Mn as of December 2025, a net change of up by 10.03Mn shares quarter on quarter, and up 12.65Mn shares year over year.
• BlackRock, Inc.'s holding of 11.35Mn shares as of December 31, 2025 makes it the primary institutional investor in Humacyte, owning 7.06% of the stock.
• Among the most significant buyers of Humacyte during December 2025 were MILLENNIUM MANAGEMENT LLC (1.49Mn), BlackRock, Inc. (1.44Mn), BNP PARIBAS FINANCIAL MARKETS (1.01Mn), UBS Group AG (976.27K), VANGUARD GROUP INC (896.92K).
• Leading sellers of Humacyte stock in December 2025 included ROYAL BANK OF CANADA (492.40K), Private Advisor Group, LLC (467.50K), MARSHALL WACE, LLP (330.58K), Waverly Advisors, LLC (247.99K), AQR CAPITAL MANAGEMENT LLC (224.24K).
• The top 10 institutional holders of Humacyte for the quarter ending December 2025 included BlackRock, Inc. (11.35Mn), VANGUARD GROUP INC (8.42Mn), GEODE CAPITAL MANAGEMENT, LLC (3.72Mn), UBS Group AG (2.98Mn), STATE STREET CORP (2.84Mn), MILLENNIUM MANAGEMENT LLC (2.63Mn), MORGAN STANLEY (2.51Mn), Woodline Partners LP (2.00Mn), CITADEL ADVISORS LLC (1.57Mn), TWO SIGMA INVESTMENTS, LP (1.49Mn).